Trial Profile
A Two-Year Multi-Centre, Randomized Two Arm Study Of Genotropin Treatment In Very Young Children Born Small For Gestational Age: Early Growth And Neurodevelopment(Egn)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Dec 2021
Price :
$35
*
At a glance
- Drugs Somatropin (Primary)
- Indications Growth disorders; Short stature
- Focus Registrational; Therapeutic Use
- Acronyms Egn
- Sponsors Pfizer
- 02 Apr 2014 New trial record
- 26 Mar 2014 Top-line results reported in a Pfizer media release.